Synonym
Nepaprazole; TY-11345; TY 11345; TY11345.
IUPAC/Chemical Name
(9R)-9-((1H-benzo[d]imidazol-2-yl)sulfinyl)-4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
InChi Key
JWMQOWBYKLZSPY-YAOANENCSA-N
InChi Code
InChI=1S/C18H19N3O2S/c1-23-15-10-11-19-17-12(15)6-2-5-9-16(17)24(22)18-20-13-7-3-4-8-14(13)21-18/h3-4,7-8,10-11,16H,2,5-6,9H2,1H3,(H,20,21)/t16-,24?/m1/s1
SMILES Code
COC1=C(CCCC[C@H]2S(C3=NC4=CC=CC=C4N3)=O)C2=NC=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
156601-79-5 (Nepaprazole)
157564-11-9 (Nepaprazole Sodium)
Preparing Stock Solutions
The following data is based on the
product
molecular weight
341.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yamada S, Goto T, Yuasa S, Yamaguchi T, Kogi K. [Synthesis of stable solvates of monosodium 2-[R*s,9S*)-(4-methoxy-6,7,8, 9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)sulfinyl]-1H-benzimidazole]. Yakugaku Zasshi. 1996 Aug;116(8):657-70. Japanese. PubMed PMID: 8831267.
2: Yamada S, Goto T, Yamaguchi T, Aihara K, Kogi K, Narita S. Synthetic study of 2-[(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9- yl)-sulfinyl]-1H-benzimidazole analogs and their biological properties as novel proton pump inhibitors. Chem Pharm Bull (Tokyo). 1995 Mar;43(3):421-31. PubMed PMID: 7774025.
3: Uematsu T, Nakano M, Kosuge K, Nagai A, Sato A, Nakashima M. Pharmacokinetic properties of a novel gastric proton pump inhibitor, (+/-)-2-[(4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9- yl)sulfinyl]-1H-benzimidazole sodium salt, in healthy subjects. J Pharm Sci. 1994 Oct;83(10):1407-11. PubMed PMID: 7884660.
4: Yamada S, Goto T, Shimanuki E, Narita S. Synthesis and antiulcer activities of novel 2-[(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)sulfinyl]-1H- benzimidazole analogues. Chem Pharm Bull (Tokyo). 1994 Mar;42(3):718-20. PubMed PMID: 8004722.
5: Yamaguchi T, Aihara K, Yamada S, Narita S, Kogi K. Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals. Jpn J Pharmacol. 1993 Aug;62(4):363-71. PubMed PMID: 8230863.